A German biotech has big ambitions in cancer. Now it needs to get a medicine approved Twenty-six years after Immatics was formed, its CEO is confident about upcoming melanoma readout By Andrew JosephOct. 21, 2026

https://www.statnews.com/2026/10/21/immatics-cancer-cell-therapy-targets-prame-protein/